Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19, US FDA Says

Executive Summary

Quarantines, travel restrictions and supply chain interruptions are likely to cause "unavoidable protocol deviations" in ongoing clinical trials, the FDA says in new guidance that encourages sponsors to consider whether alternative means for conducting safety assessments and collecting efficacy data should be implemented in light of the disruptions caused by COVID-19.

You may also be interested in...



FDA: COVID-19 Vaccine Recipients Shouldn’t Be Shut Out of Clinical Trials

Clinical trials often exclude patients who are receiving other investigational treatments. But treatments such as vaccines that have been authorized via emergency use authorizations don’t count as “investigational,” the agency says.

Informed Consent: For COVID-Affected Studies, A Handwritten Document May Suffice

Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol, and texting or emailing a photo of the signed document to the investigator, the US FDA says in its latest guidance update.

For COVID-Impacted Studies, FDA Loosens Video Conferencing Rules

Use of alternative labs or imaging centers depends upon type of assessment and reason it is being performed, the US agency's revised guidance states; missed milestones for postmarketing studies required under accelerated approval will need to be justified.

Related Content

Topics

UsernamePublicRestriction

Register

MT126426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel